GlassScriptPhysician profile
Justin Berman
NPI 1497010664
$2,556.62
in general payments reported to CMS, 2019-2025
22 companies · $754 in 2025
The $754 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $524 · 2023: $530 · 2024: $582 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,865.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $452.99 | 2021-2025 | Biktarvy |
| Viiv Healthcare Company | $398.81 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Lilly USA, LLC | $373.28 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $210.37 | 2023-2025 | |
| Exact Sciences Corporation | $171.61 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $155.60 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $113.97 | 2024-2025 | Eliquis, Camzyos |
| Janssen Biotech, INC. | $107.15 | 2021-2023 | Symtuza |
| Medtronic, INC. | $87.90 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Abbott Laboratories | $85.82 | 2022-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $70.56 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $61.07 | 2025 | Capvaxive, Gardasil 9 |
| Glaxosmithkline, LLC. | $51.20 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Cequr Corporation | $51.14 | 2024-2025 | Cequr Simplicity |
| Pfizer INC. | $38.22 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $23.77 | 2025 | Paragard T 380a |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.02 | 2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $18.17 | 2025 | Uzedy |
| Sanofi-Aventis U.S. LLC | $17.61 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.75 | 2024 | Gvoke Hypopen |
| Aimmune Therapeutics, INC. | $15.83 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.